SLC22A1 is a transporter of organic cations and monoamines, as well as anticancer drugs, whose down-regulation has been reported in hepatocellular carcinoma [51,52], breast carcinoma [53], pancreatic carcinoma [54], and cholangiocellular carcinoma [55]. This evidence concerns the gene SLC22A1 and exocrine pancreatic carcinoma.